India’s biotech and pharmaceutical R&D journey began much earlier than many believe, with its foundations laid in the 1990s and early 2000s. Indian companies, inspired by global multinationals such as Pfizer, Merck, and Novartis, invested heavily in

Today, ensuring innovation remains accessible is paramount. We are now able to deliver therapies like CAR-T at 5–8% of the cost compared to the U.S., without compromising on quality or outcomes. Currently, India’s strategic investments in local manuf

Viren Shetty, Executive Vice Chairman of Narayana Health, emphasized that drugs alone cannot transform outcomes—India needs integration between hospitals, insurers, and pharma to ensure innovation reaches patients at scale.

In an interaction with Thiruamuthan, Correspondent, India Pharma Outlook, Anjali Ajaikumar, Director, Milann Fertility & Birthing Hospital, discusses the rising infertility challenge, evolving fertility treatments, and innovations shaping personalize

In an exclusive interview with Thiruamuthan, Correspondent at India Pharma Outlook, Aditya Sharma, Head of Process Solutions, India Region, Merck Life Science, discusses how a dedicated formulation and technology centre addresses complex challenges i

In an interaction with India Pharma Outlook, Deepak Ghagare, Associate Director SBS, Spectrum Pharmatech shares insights on India’s evolving HPAPI manufacturing landscape, emphasizing advanced containment strategies and regulatory alignment.